Zobrazeno 1 - 10
of 132
pro vyhledávání: '"Charles A. Koller"'
Autor:
Kevin Kalinsky, John K. Erban
Publikováno v:
New England Journal of Medicine. 355:2709-2710
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7e56c6d9b32b4a0e514b2b6813cef3a
https://doi.org/10.1056/nejmbkrev57246
https://doi.org/10.1056/nejmbkrev57246
Autor:
Susan Lerner, Jan A. Burger, Xuemei Wang, Michael J. Keating, Alessandra Ferrajoli, Susan O'Brien, Stefan Faderl, William G. Wierda, Hagop M. Kantarjian, Charles A. Koller, Xavier Badoux
Publikováno v:
Blood. 117:3016-3024
Optimal management of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) is dictated by patient characteristics, prior therapy, and response to prior therapy. We report the final analysis of combined fludarabine, cyclophosphamide, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e63497662926ba6e1f44253d64ac5f51
https://doi.org/10.1182/blood-2010-08-304683
https://doi.org/10.1182/blood-2010-08-304683
Autor:
Javier Loscertales, Michael J. Keating, Deborah A. Thomas, Hagop M. Kantarjian, Francis J. Giles, Jorge E. Cortes, Susan O'Brien, Charles A. Koller
Publikováno v:
Cancer. 92:2016-2022
BACKGROUND Autoimmune cytopenias are a frequent complication in patients with chronic lymphocytic leukemia (CLL). Anecdotal reports suggest that cyclosporin A (CsA) may be beneficial for patients with CLL-associated pure red cell aplasia. In the curr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07ae9f2eff8b7ab73327394bee846b67
https://doi.org/10.1002/1097-0142(20011015)92:8<2016::aid-cncr1539>3.0.co
https://doi.org/10.1002/1097-0142(20011015)92:8<2016::aid-cncr1539>3.0.co
Autor:
Charles A. Koller, Elihu H. Estey, Deborah A. Thomas, Hagop Kantarjian, Jorge Cortes, Miloslav Beran, Stefan Faderl, Simona Despa, Francis J. Giles, Susan O'Brien, Yu Shen
Publikováno v:
Cancer. 92:1999-2015
BACKGROUND Antileukemic chemotherapy has been used for two decades to treat high-risk myelodysplastic syndrome (refractory anemia with excess of blasts [RAEB] and RAEB in transformation into acute leukemia [RAEB-t]) patients. Because the results of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43c738521a39581cc1aa87698d9ceb79
https://doi.org/10.1002/1097-0142(20011015)92:8<1999::aid-cncr1538>3.0.co
https://doi.org/10.1002/1097-0142(20011015)92:8<1999::aid-cncr1538>3.0.co
Autor:
Carl Plager, C R N Carolyn Gorski, Nicholas E. Papadopoulos, Charles A. Koller, Sewa S. Legha, Robert S. Benjamin
Publikováno v:
Cancer. 73:236-239
Background. Lomustine is a commercially available chloroethyl nitrosourea compound whose antitumor activity in vitro and in animal tumor models exceeds its activity in humans. Part of the poor clinical performance of this drug may be explained by dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebba579afac82115a3d9984f45949afe
https://doi.org/10.1002/1097-0142(19940101)73:1<236::aid-cncr2820730140>3.0.co
https://doi.org/10.1002/1097-0142(19940101)73:1<236::aid-cncr2820730140>3.0.co
Autor:
Rajyalakshmi Luthra, Jan A. Burger, Pramoda Challagundla, Sergernne York, Sherry Pierce, Deborah A. Thomas, Jeffrey L. Jorgensen, Stefan Faderl, Mark Brandt, Susan O'Brien, Alessandra Ferrajoli, Charles A. Koller, Farhad Ravandi, Michael J. Keating, Hagop M. Kantarjian
We conducted this study to determine the feasibility and safety of cladribine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv). Cladribine 5.6 mg/m2 given IV over 2 hours daily for 5 days was followed ∼
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d0dd817c22f2e33fe33810e664c2801
https://europepmc.org/articles/PMC4081440/
https://europepmc.org/articles/PMC4081440/
Autor:
William G. Wierda, Susan O'Brien, Michael J. Keating, Sameer A. Parikh, Susan Lerner, Zeev Estrov, Alessandra Ferrajoli, Xavier Badoux, Stefan Faderl, Jan A. Burger, Charles A. Koller, Xuemei Wang
Publikováno v:
Blood. 118(8)
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae006b22fe15fdb43a71f304498b0da8
https://pubmed.ncbi.nlm.nih.gov/21750315
https://pubmed.ncbi.nlm.nih.gov/21750315
Publikováno v:
Therapeutic Drug Monitoring. 14:255-260
This article describes a method for the determination of plicamycin in plasma by radioimmunoassay. The anti-plicamycin antibody was produced against a plicamycin-bovine serum albumin conjugate prepared by using diazotized p-aminobenzoic acid as a cro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03ef19b996f86868c01d3d212cfb4b84
https://doi.org/10.1097/00007691-199206000-00013
https://doi.org/10.1097/00007691-199206000-00013
Autor:
Constantine S. Tam, Susan O'Brien, Charles A. Koller, Elias Jabbour, William G. Wierda, Dan Jones, Gautam Borthakur, Hagop M. Kantarjian, Jorge E. Cortes, Jan A. Burger
Publikováno v:
Blood. 114(10)
Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating switch to one of several new tyrosine kinase inhibitors (TKIs) that act differentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd1f2bb65f4bc2d93e75636d5d8d4381
https://pubmed.ncbi.nlm.nih.gov/19567878
https://pubmed.ncbi.nlm.nih.gov/19567878
Autor:
Guillermo Garcia-Manero, Sherry Pierce, Stefan Faderl, Michael J. Keating, Charles A. Koller, Susan O'Brien, Deborah A. Thomas, Yang Huh, William G. Wierda, Jeffrey L. Jorgensen, Srdan Verstovsek, Hagop M. Kantarjian, Jorge E. Cortes
Immunophenotypic classification of acute lymphoblastic leukemia (ALL) has well-recognized prognostic implications. The significance of CD20 expression has been evaluated in childhood precursor B-lineage ALL with conflicting results. We retrospectivel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c870f683c1abbf5b1cb82bc28dab583e
https://europepmc.org/articles/PMC2943753/
https://europepmc.org/articles/PMC2943753/